Competition law vs patent rights: NCLAT rules CCI has no power to probe patented product disputes; upholds case against Swiss drugmaker Vifor
Competition law vs patent rights: NCLAT rules CCI has no power to probe patented product disputes; upholds case against Swiss drugmaker Vifor
The NCLAT ruled that the CCI cannot investigate disputes concerning patented products, asserting the Patent Act's precedence over the Competition Act. This decision dismissed an appeal against the CCI's closure of a complaint against Vifor International regarding its patented drug, Ferric Carboxymaltose (FCM) injection.
The NCLAT ruled that the CCI cannot investigate disputes concerning patented products, asserting the Patent Act's precedence over the Competition Act. This decision dismissed an appeal against the CCI's closure of a complaint against Vifor International regarding its patented drug, Ferric Carboxymaltose (FCM) injection.
The NCLAT ruled that the CCI cannot investigate disputes concerning patented products, asserting the Patent Act's precedence over the Competition Act. This decision dismissed an appeal against the CCI's closure of a complaint against Vifor International regarding its patented drug, Ferric Carboxymaltose (FCM) injection. 
